Top

Published in:

01-12-2009 | Review

Targeting insulin-like growth factor type 1 receptor in cancer therapy

Authors: Francesco Atzori, Tiffany A. Traina, Maria Teresa Ionta, Bruno Massidda

Published in: Targeted Oncology | Issue 4/2009

Abstract

It is believed that the insulin-like growth factor receptor type 1 (IGF-1R) signaling pathway plays a pivotal role in cancer growth, progression, and resistance to anticancer therapies. Strategies are being developed to block IGF-1R as an anticancer treatment. We reviewed several potential strategies for disrupting the IGF axis. We also reviewed the effects of two drugs that target the IGF-1R: monoclonal antibodies and tyrosine kinase inhibitors. Preliminary results of studies involving these agents provided a foundation for ongoing clinical trials, whose results in the near future will help us understand how to incorporate anti IGF-1R strategies into the current anticancer armamentarium.

Pollak MN, Schernhammer ES, Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4:505–418CrossRefPubMed

Hankinson SE, Willett WC, Colditz GA et al (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351(9113):1393–1396CrossRefPubMed

Roddam AW, Allen NE, Appleby P et al (2008) Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 149(7):461–471PubMed

Ma J, Pollak MN, Giovannucci E et al (1999) Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91(7):620–625CrossRefPubMed

Ouban A, Muraca P, Yeatman T et al (2003) Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol 34(8):803–908CrossRefPubMed

Camirand A, Zakikhani M, Young F et al (2005) Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res 7(4):570–579CrossRef

Jones HE, Goddard L, Gee JM et al (2004) Insulin-like growth factor-I receptor signaling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 11(4):793–814CrossRefPubMed

Chakravarti A, Loeffler JS, Dyson NJ (2002) Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62(1):200–207PubMed

Liu B, Fang M, Lu Y et al (2001) Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody. Oncogene 20(15):1913–1922CrossRefPubMed

10.

Sakamoto M, Kondo A, Kawasaki K et al (2001) Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Hum Cell 14(4):305–315PubMed

11.

Shimizu C, Hasegawa T, Tani Y et al (2004) Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis. Hum Pathol 35(12):1537–1542CrossRefPubMed

12.

Abe S, Funato T, Takahashi S et al (2006) Increased expression of insulin-like growth factor i is associated with Ara-C resistance in leukemia. Tohoku J Exp Med 209(3):217–228CrossRefPubMed

13.

Cappuzzo F, Toschi L, Tallini G, Ceresoli GL, Domenichini I, Bartolini S et al (2006) Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 17(7):1120–1127CrossRefPubMed

14.

Friedrich N, Haring R, Nauck M et al (2009) Mortality and serum insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. J Clin Endocrinol Metab 94(5):1732–1739CrossRefPubMed

15.

Rowlands MA, Gunnell D, Harris R et al (2009) Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer 124(10):2416–2429CrossRefPubMed

16.

Papadimitrakopoulou VA, Brown EN, Liu DD et al (2006) The prognostic role of loss of insulin-like growth factor-binding protein-3 expression in head and neck carcinogenesis. Cancer Lett 239(1):136–143CrossRefPubMed

17.

Chang YS, Wang L, Suh YA, Mao L, Karpen SJ, Khuri FR et al (2004) Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer. Oncogene 23(39):6569–6580CrossRefPubMed

18.

Baglietto L, English DR, Hopper JL et al (2007) Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 16(4):763–768CrossRefPubMed

19.

Nedic O, Malenkovic V, Dukanovic B et al (2008) Association of elevated IGFBP-1 with increased IGF-II concentration in patients with carcinoma of the liver. Int J Biol Markers 23(4):225–230PubMed

20.

Renehan AG, Jones J, Potten CS et al (2000) Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. Br J Cancer 83(10):1344–1350CrossRefPubMed

21.

Rikhof B, van Doorn J, Suurmeijer AJ et al (2009) Insulin-like growth factors and insulin-like growth factor-binding proteins in relation to disease status and incidence of hypoglycaemia in patients with a gastrointestinal stromal tumour. Ann Oncol 20(9):1582–1588CrossRefPubMed

22.

Lin Y, Jiang T, Zhou K et al (2009) Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. Neuro Oncol. doi:10.1215/15228517-2008-114 PubMed

23.

Letsch M, Schally AV, Busto R et al (2003) Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers. Proc Natl Acad Sci U S A 100(3):1250–1255CrossRefPubMed

24.

Thorner MO, Strasburger CJ, Wu Z et al (1999) Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. J Clin Endocrinol Metab 84(6):2098–2103CrossRefPubMed

25.

Schreiber I, Buchfelder M, Droste M et al (2007) Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 156(1):75–82CrossRefPubMed

26.

Yin D, Vreeland F, Schaaf LJ et al (2007) Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. Clin Cancer Res 13(3):1000–1009CrossRefPubMed

27.

Divisova J, Kuiatse I, Lazard Z et al (2006) The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat 98(3):315–327CrossRefPubMed

28.

McCutcheon IE, Flyvbjerg A, Hill H et al (2001) Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J Neurosurg 94(3):487–492CrossRefPubMed

29.

Goya M, Miyamoto S, Nagai K et al (2004) Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Res 64(17):6252–6258CrossRefPubMed

30.

Arteaga CL, Kitten LJ, Coronado EB et al (1989) Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 84(5):1418–1423CrossRefPubMed

31.

Pollak M (2008) Targeting insulin and insulin-like growth factor signaling in oncology. Curr Opin Pharmacol 8(4):384–392CrossRefPubMed

32.

Munshi S, Hall DL, Kornienko M et al (2003) Structure of apo, unactivated insulin-like growth factor-1 receptor kinase at 1.5 A resolution. Acta Crystallogr D Biol Crystallogr 59(Pt 10):1725–1730CrossRefPubMed

33.

Pollak M (2008) Insulin, insulin-like growth factors and neoplasia. Best Pract Res Clin Endocrinol Metab 22(4):625–638CrossRefPubMed

34.

Hofmann F, Garcia-Echeverria C (2005) Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov Today 10(15):1041–1047CrossRefPubMed

35.

Cohen BD, Baker DA, Soderstrom C et al (2005) Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751, 871. Clin Cancer Res 11(5):2063–2073CrossRefPubMed

36.

Haluska P, Shaw HM, Batzel GN et al (2007) Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751, 871 in patients with refractory solid tumors. Clin Cancer Res 13(19):5834–5840CrossRefPubMed

37.

Lacy MQ, Alsina M, Fonseca R et al (2008) Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751, 871 in patients with multiple myeloma. J Clin Oncol 26(19):3196–3203CrossRefPubMed

38.

Karp DD, Paz-Ares LG, Blakely LJ et al (2007) Efficacy of the anti-insulin like growth factor I receptor (IGF-IR) antibody CP-751871 in combination with paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC). J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. 25(18S):7506

39.

Karp DD, Pollak MN, Cohen RB, Eisenberg PD, Haluska P, Yin D, Lipton A, Demers L, Leitzel K, Hixon ML, Terstappen LW, Garland L, Paz-Ares LG, Cardenal F, Langer CJ, Gualbert A (2009) Safety, pharmacokinetics and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751, 871) in combination with paclitaxel and carboplatin. J Thorac Oncol. doi:10.1097/JTO.0b013e3181ba2f1d

40.

Study of CP-751,871 in Combination With Sunitinib in Patients With Advanced Solid Tumors. http://clinicaltrials.gov/show/NCT00729833. Accessed 28 Sept 2009

41.

A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks. http://clinicaltrials.gov/show/NCT00728390. Accessed 28 Sept 2009

42.

Study Of CP-751,871 In Combination With Cisplatin And Gemcitabine In Chemotherapy-Naïve Patients With Advanced Non-Small Cell Lung Cancer. http://clinicaltrials.gov/show/NCT00560573. Accessed 28 Sept 2009

43.

Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer. http://clinicaltrials.gov/ct2/show/NCT00678626. Accessed 28 Sept 2009

44.

Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC). http://clinicaltrials.gov/show/NCT00313781. Accessed 28 Sept 2009

45.

Postel-Vinay S, Okuno S, Schuetze S et al (2008) Safety, pharmacokinetics and preliminary activity of the anti-IGF-IR antibody CP-751,871 in patients with sarcoma. 20th EORTC–NCI–AACR Symposium on Molecular Targets and Cancer Therapeutics. Proceedings Eur J Cancer 6(12) 2008, abstract 388

46.

Study of CP-751,871 In combination with exemestane in postmenopausal women with Hormone Receptor Positive Advanced Breast Cancer. http://clinicaltrials.gov/show/NCT00372996. Accessed 28 Sept 2009

47.

Study Using CP-751,871 In Patients With Stage IV Colorectal Cancer That Has Not Responded To Previous Anti-Cancer Treatments. http://clinicaltrials.gov/show/NCT00560560. Accessed 28 Sept 2009

48.

Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer (NSCLC). http://clinicaltrials.gov/show/NCT00673049. Accessed 28 Sept 2009

49.

Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology. http://clinicaltrials.gov/show/NCT00596830. Accessed 28 Sept 2009

50.

Burtrum D, Zhu Z, Lu D et al (2003) A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 63:8912–8921PubMed

51.

Rowinsky EK, Youssoufian H, Tonra JR et al (2007) (2007) IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 13(18 Pt 2):5549s–5555sCrossRefPubMed

52.

Higano CS, Yu EY, Whiting SH et al (2007) A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors. J Clin Oncol 25(18 S): abstract 3505

53.

Rothenberg ML et al (2007) Phase I dose-escalation study of the anti-IGF-IR recombinant human IgG1 monoclonal antibody (Mab) IMC-A12, administered every other week to patients with advanced solid tumors. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, abstract C84

54.

A Five-Tier, Phase 2 Open-Label Study of IMC-A12 Administered as a Single Agent. http://clinicaltrials.gov/show/NCT00668148. Accessed 28 Sept 2009

55.

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors. http://clinicaltrials.gov/ct/show/NCT00831844. Accessed 28 Sept 2009

56.

A Study of IMC-A12 in Adrenocortical Cancer. http://clinicaltrials.gov/show/NCT00810537. Accessed 28 Sept 2009

57.

Monoclonal Antibody IMC-A12 and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer. http://clinicaltrials.gov/ct/show/NCT00678223. Accessed 28 Sept 2009

58.

Cixutumumab and Temsirolimus in Treating Young Patients With Solid Tumors That Have Recurred or Not Responded to Treatment. http://clinicaltrials.gov/ct/show/NCT00880282. Accessed 28 Sept 2009

59.

IMC-A12 and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer. http://clinicaltrials.gov/ct/show/NCT00699491. Accessed 28 Sept 2009

60.

Monoclonal Antibody IMC-A12 and Doxorubicin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma. http://clinicaltrials.gov/ct/show/NCT00720174. Accessed 28 Sept 2009

61.

Study of IMC-A12, Alone or in Combination With Cetuximab, in Patients With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck. http://clinicaltrials.gov/show/NCT00617734. Accessed 28 Sept 2009

62.

Capecitabine and Lapatinib With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Treated HER2-Positive Stage IIIB, Stage IIIC, or Stage IV Breast Cancer. http://clinicaltrials.gov/ct/show/NCT00684983. Accessed 28 Sept 2009

63.

Study Using IMC-A12 or IMC-1121B Plus Mitoxantrone and Prednisone in Metastatic Androgen-Independent Prostate Cancer, Following Disease Progression on Docetaxel-Based Chemotherapy. http://clinicaltrials.gov/show/NCT00683475. Accessed 28 Sept 2009

64.

A Study for Safety and Effectiveness of IMCA12 by Itself or Combined With Antiestrogens to Treat Metastatic Breast Cancer in Patients Who Progressed on Antiestrogen Therapy. http://clinicaltrials.gov/show/NCT00728949. Accessed 28 Sept 2009

65.

Mitotane With or Without IMC-A12 in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery. http://clinicaltrials.gov/ct/show/NCT00778817. Accessed 28 Sept 2009

66.

Erlotinib With or Without IMC-A12 in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer. http://clinicaltrials.gov/ct/show/NCT00778167. Accessed 28 Sept 2009

67.

Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer. http://clinicaltrials.gov/show/NCT00769795. Accessed 28 Sept 2009

68.

Multicenter Study of IMC-A12 in Combination With Depot Octreotide in Patients With Carcinoid or Islet Cell Cancer. http://clinicaltrials.gov/show/NCT00781911. Accessed 28 Sept 2009

69.

A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of People With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab (FC-4). http://clinicaltrials.gov/show/NCT00845039. Accessed 28 Sept 2009

70.

A Study to Test IMC-A12 With and Without Other Standard Chemotherapies in Patients With Lung Cancer Who Have Not Received Chemotherapy Before. http://clinicaltrials.gov/show/NCT00870870. Accessed 28 Sept 2009

71.

Beltran P, Mitchell P, Hwang D et al (2007) Inhibition of endocrine IGF-1 signaling in normal murine tissues and human tumor xenografts with AMG 479, a fully human anti IGF-1R monoclonal antibody. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, 2007, abstract A67

72.

Calzone F, Chung YA, Cajulis E et al (2008) Domain-specific mechanisms of receptor inhibition by AMG 479, a fully-human IGF1R targeted antibody. 99th AACR Annual Meeting 2008, abstract 3994

73.

Moody G, Mitchell P, Cajulis E et al (2007) AMG 479, a fully human anti IGF-1 receptor monoclonal antibody, is efficacious against Ewing’s sarcoma and osteosarcoma xenografts. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, 2007, abstract A64

74.

Tolcher AW, Rothenberg ML, Rodon J, et al. A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors. J Clin Oncol2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18 S Suppl; abstr: 3002

75.

Sarantopoulos J, Mita AC, Mulay M et al (2008) A phase IB study of AMG-479, a type 1 insulin-like growth factor receptor (IGF1R) anitbody, in combination with panitumumab (P) or gemcitabine (G). J Clin Oncol 26(15S):3583

76.

A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing’s Family Tumor and Desmoplastic Small Round Cell Tumors. http://clinicaltrials.gov/show/NCT00563680. Accessed on 28 Sept 2009

77.

Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-Sensitive Ovarian Cancer. http://clinicaltrials.gov/show/NCT00719212. Accessed on 28 Sept 2009

78.

A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer. http://clinicaltrials.gov/show/NCT00630552. Accessed on 28 Sept 2009

79.

Panitumumab Combination Study With AMG 102 or AMG 479 in Wild-Type KRAS mCRC. http://clinicaltrials.gov/show/NCT00788957. Accessed on 28 Sept 2009

80.

A Phase 1b/2 Trial of AMG 479 or AMG 102 in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer. http://clinicaltrials.gov/show/NCT00791154. Accessed on 28 Sept 2009

81.

Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer. http://clinicaltrials.gov/show/NCT00807612. Accessed on 28 Sept 2009

82.

AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors. http://clinicaltrials.gov/show/NCT00819169. Accessed on 28 Sept 2009

83.

Amgen Protocol No. 20060362 - A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer. http://clinicaltrials.gov/show/NCT00626106. Accessed on 28 Sept 2009

84.

Phase 2 Safety & Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 vs FOLFIRI in KRAS-Mutant Metastatic Colorectal Carcinoma. http://clinicaltrials.gov/show/NCT00813605. Accessed on 28 Sept 2009

85.

Goetsch L, Gonzalez A, Leger O et al (2005) Recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 113:316–328CrossRefPubMed

86.

Atzori F, Tabernero J, Cervantes A et al (2008) A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors. J Clin Oncol 26(15S): abstract 3519

87.

Hidalgo M, Tirado Gomez M, Lewis N et al (2008) A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule. J Clin Oncol 26(15S): abstract 3520

88.

A Study of MK0646 in Breast Cancer Patients. http://clinicaltrials.gov/show/NCT00759785. Accessed on 28 Sept 2009

89.

A Combination Study With MK8669 and MK0646 in Patients With Advanced Cancer. http://clinicaltrials.gov/show/NCT00730379. Accessed on 28 Sept 2009

90.

MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer (IMPACT). http://clinicaltrials.gov/show/NCT00799240. Accessed on 28 Sept 2009

91.

Phase I Imaging Study Evaluating MK0646 in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer. http://clinicaltrials.gov/show/NCT00729742. Accessed on 28 Sept 2009

92.

MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer. http://clinicaltrials.gov/ct/show/NCT00869752. Accessed on 28 Sept 2009

93.

Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET). http://clinicaltrials.gov/show/NCT00610129. Accessed on 28 Sept 2009

94.

MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer. http://clinicaltrials.gov/show/NCT00769483. Accessed on 28 Sept 2009

95.

Study of MK0646 in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer. http://clinicaltrials.gov/show/NCT00614393. Accessed on 28 Sept 2009

96.

Rodon J, Patnaik A, Stein M et al (2007) A phase I study of q3W R1507, a human monoclonal antibody IGF-1R antagonist in patients with advanced cancer. J Clin Oncol 25(18S):3590

97.

A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors. http://clinicaltrials.gov/show/NCT00560144. Accessed on 28 Sept 2009

98.

A Study of R1507 in Patients With Recurrent or Refractory Sarcoma. http://clinicaltrials.gov/show/NCT00642941. Accessed on 28 Sept2009

99.

A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC). http://clinicaltrials.gov/show/NCT00760929. Accessed on 28 Sept 2009

100.

A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy. http://clinicaltrials.gov/show/NCT00773383. Accessed on 28 Sept 2009

101.

A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer. http://clinicaltrials.gov/show/NCT00796107. Accessed on 28 Sept 2009

102.

A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors. http://clinicaltrials.gov/show/NCT00811993. Accessed on 28 Sept 2009

103.

Maloney EK, McLaughlin JL, Dagdigian NE et al (2003) An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 63:5073–5083PubMed

104.

Dallas NA, Xia L, Fan F et al (2009) Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 69(5):1951–1957CrossRefPubMed

105.

Descamps G, Gomez-Bougie P, Venot C et al (2009) A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45. Br J Cancer 100(2):366–369CrossRefPubMed

106.

Moreau P, Hulin C, Facon T et al (2007) Phase I study of AVE1642 Anti IGF-1R monoclonal antibody in patients with multiple myeloma. ASH Annual Meeting Abstracts. Blood 11:1166

107.

Tolcher AW, Patnaik A, Till E et al (2008) A phase I study of AVE1642, a humanized monoclonal antibody IGF-1R (Insulin like growth factor 1 receptor) antagonist, in patients (pts) with advanced solid tumor (ST). J Clin Oncol 26(15 S): abstract 3582

108.

Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma. http://clinicaltrials.gov/show/NCT00791544. Accessed on 28 Sept 2008

109.

Kolb EA, Gorlick R, Houghton PJ et al (2008) Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 50(6):1190–1197CrossRefPubMed

110.

Seraj J, Tsai M, Seiberling M et al (2007) Evaluation of safety and pharmacokinetics of a fully human IGF-1 receptor antibody, SCH 717454, in healthy volunteers. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2007, Abstract A72

111.

A Study to Determine the Activity of SCH 717454 in Subjects With Relapsed Osteosarcoma or Ewing’s Sarcoma (Study P04720). http://clinicaltrials.gov/show/NCT00617890. Accessed on 28 September 2008

112.

A Study to Determine the Activity of SCH 717454 in Subjects With Relapsed or Recurrent Colorectal Cancer (Study P04721AM1). http://clinicaltrials.gov/show/NCT00551213. Accessed on 28 September 2008

113.

Hariharan K, Dong J; Demarest S et al (2007) BIIB022, a fully human nonglycosylated γ4P antibody targeting IGF-1R for cancer therapy. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2007, abstract B210

114.

Dong J, Tamraz S, Berquist L et al (2008) BIIB022, a human antibody targeting human insulin-like growth factor-1 receptor (IGF-1R), enhances the antitumor activities of Tarceva in non small cell lung carcinoma (NSCLC) and Rapamycin in sarcoma cell lines. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; 2008. Abstr. 4002.

115.

Cortes J, Paquette R, Talpaz M et al (2008) Preliminary Clinical Activity in a Phase I Trial of the BCR-ABL/IGF- 1R/Aurora Kinase Inhibitor XL228 in Patients with Ph⁺+ Leukemias with Either Failure to Multiple TKI Therapies or with T315I Mutation. ASH Annual Meeting Abstracts Blood 112:3232

116.

Smith DC, C. Britten C, Clary DO et al (2009) A phase I study of XL228, a potent IGF1R/AURORA/SRC inhibitor, in patients with solid tumors or hematologic malignancies. J Clin Oncol 27(15S): abstract 3512

117.

Harzstark AL, Ryan C, Diamond M et al (2007) A phase I trial of nordihydroguareacetic acid (NDGA) in patients with non-metastatic prostate cancer and rising PSA. J Clin Oncol 25(18S) abstract 15500

118.

Pharmacokinetic and Efficacy Study of Nordihydroguaiaretic Acid (NDGA) in Non Metastatic Recurrent Prostate Cancer. http://clinicaltrials.gov/show/NCT00678015. Accessed on 28 Sept 2008

119.

Werner H, Woloschak M, Adamo M et al (1989) Developmental regulation of the rat insulin-like growth factor I receptor gene. Proc Natl Acad Sci U S A 86(19):7451–7455CrossRefPubMed

120.

Benyoucef S, Surinya KH, Hadaschik D, Siddle K (2007) Characterization of insulin/IGF hybrid receptors: contributions of the insulin receptor L2 and Fn1 domains and the alternatively spliced exon 11sequence to ligand binding and receptor activation. Biochem J 403:603–613CrossRefPubMed

121.

Lammers R, Gray A, Schlessinger J, Ullrich A (1989) Differential signalling potential of insulin- and IGF-1-receptor cytoplasmic domains. EMBO J 8:1369–1375PubMed

122.

Belfiore A (2007) The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 13:671–686CrossRefPubMed

123.

Gualberto A, Pollak M (2009) Clinical Development of Inhibitors of the Insulin-like Growth Factor Receptor in Oncology. Curr Drug Targets. Oct 1 epublication

124.

Gualberto A, Karp DD (2009) Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer. Clin Lung Cancer 10(4):273–280CrossRefPubMed

125.

Olmos D, Molife R, Okuno S, Worden F, Hammer G, Yap T et al (2007) Safety, tolerability and preliminary efficacy of the anti-IGFIR monoclonal antibody CP-751,871 in patients with sarcomas and adrenocortical tumors. Presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting, San Francisco, USA, 22–26, October 2007

126.

Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4):337–345CrossRefPubMed

127.

Thomson S, Buck E, Petti F et al (2005) Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 65:9455–9462CrossRefPubMed

128.

Pandini G, Wurch T, Akla B et al (2007) Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors. Eur J Cancer 43:1318–1327CrossRefPubMed

129.

Huang FHW, Hafezi R, Han X et al (2007) Identification of sensitivity markers for BMS-536924, an inhibitor for insulin-like growth factor-1 receptor. ASCO Ann Meet Proc 2007. J Clin Oncol 25:3506

130.

Pollak MNLM, Lipton A, Demers L (2007) Pharmacodynamic properties of the anti-IGF-IR monoclonal antibody CP-751,871 in cancer patients. ASCO Ann Meet Proc 2007. J Clin Oncol 25:3587CrossRef

131.

Scotlandi K (2006) Targeted therapies in Ewing’s sarcoma. Adv Exp Med Biol 587:13–22PubMed

132.

Ji QS, Mulvihill M, Franklin M et al (2007) Properties of small molecule IGF-IR kinase inhibitors in preclinical models. AACR Annual Meeting 2007, Los Angeles (CA): abstract 30.9

Title: Targeting insulin-like growth factor type 1 receptor in cancer therapy
Authors: Francesco Atzori
Tiffany A. Traina
Maria Teresa Ionta
Bruno Massidda
Publication date: 01-12-2009
Publisher: Springer-Verlag
Published in: Targeted Oncology / Issue 4/2009
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-009-0123-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2009

Targeted therapies in thyroid cancer

Implications of KRAS mutation status for the treatment of metastatic colorectal cancer

Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon?

Sunitinib paves the way for targeted therapies in neuroendocrine tumors

Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors

Molecular targeted therapies in the treatment of gastroenteropancreatic neuroendocrine tumors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer